Form 4: Supernus Director Sells Shares Under 10b5-1 Plan

Supernus Pharmaceuticals Director Bethany Sensenig sold 5,369 shares of common stock for $42.25 per share under a pre-arranged 10b5-1 trading plan.

Summary

• Supernus Pharmaceuticals, Inc. Director Bethany Sensenig sold 5,369 shares of the company's common stock.
• The transaction occurred on August 14, 2025, at a weighted average price of $42.25 per share.
• The shares were sold in multiple transactions with prices ranging from $41.88 to $42.52.
• This sale was conducted pursuant to a Rule 10b5-1 trading plan, which was adopted on May 15, 2025.
• Following this reported transaction, the reporting person's direct beneficial ownership of Supernus common stock is 0 shares.

Sentiment

Score: 5

Explanation: The filing reports an insider sale of common stock by a director. While insider selling can sometimes be perceived negatively, the transaction was executed under a pre-arranged 10b5-1 trading plan, which suggests the sale was planned in advance and not based on new, non-public information. The director now holds no direct shares.

Positives

• The sale was executed under a pre-arranged Rule 10b5-1 trading plan, indicating a scheduled transaction rather than a reaction to new, non-public information.

Negatives

• A director has divested all their directly held common stock in the company.

Risks

• The complete divestment of direct shares by a director, even under a 10b5-1 plan, could be perceived by some investors as a lack of long-term commitment or confidence, potentially impacting investor sentiment.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: May interpret the director's complete divestment of direct holdings as a signal, though the 10b5-1 plan mitigates the immediate negative implication.

Key Dates

Recommendation

The filing details a pre-planned insider sale by a director, which is a routine disclosure and does not inherently signal a change in the company's fundamental outlook. While the director sold all directly held shares, the 10b5-1 plan indicates the transaction was scheduled in advance, mitigating concerns about new negative information. Investors should consider this as a data point within a broader analysis of the company's financial performance and strategic direction.

Keywords

Supernus Pharmaceuticals, SUPN, Insider Trading, Form 4, Stock Sale, Director, 10b5-1 Plan, Equity Transaction